Literature DB >> 15880372

Thyroid cancer and multiple primary tumors in the SEER cancer registries.

Cécile M Ronckers1, Peter McCarron, Elaine Ron.   

Abstract

Thyroid cancer incidence rates have increased steadily in the United States and elsewhere. Radiation exposure at a young age is a strong risk factor, but otherwise the etiology is unclear. To explore etiologic clues, we studied the risk of thyroid cancer after an earlier primary cancer, as well as the risk of developing multiple primaries after an earlier thyroid cancer in the U.S. Surveillance, Epidemiology and End-Results (SEER) cancer registries program (1973-2000). In 2,036,597 patients diagnosed with any invasive cancer who survived for a minimum of 2 months, we observed a 42% increased risk compared to the general population for second thyroid cancer based on 1,366 cases (95% confidence interval (CI) = 35-50%; excess absolute risk (EAR) = 0.38/10,000 person-years (PY)). Elevated risks were observed after most cancer sites studied. The most pronounced excess (observed/expected (O/E) = 2.86) was seen for second thyroid cancers detected in the year after diagnosis of the first cancer. Among 29,456 2-month thyroid cancer survivors, 2,214 second cancers occurred (O/E = 1.11, 95% CI = 1.06-1.15; EAR = 7.64/10,000 PY). Again, the highest risk was seen in the first year (O/E = 1.26). Patients <40 years of age at diagnosis of thyroid cancer had a 39% increased risk of a second cancer, whereas for older patients the risk was elevated 6%. We observed consistently increased risks for cancers of the breast, prostate, and kidney, and a likely radiation treatment-related excess of leukemia. Based on small numbers of cases, cancers of the salivary glands, trachea, scrotum, adrenal glands, and brain and central nervous system (CNS) also occurred in excess. A decreased risk was observed for smoking-related malignancies. Thyroid cancer is associated with primary cancers of many different organs. Although enhanced medical surveillance likely plays a role, 2-way, positive associations between thyroid cancer and cancers of the breast, prostate, kidney, salivary glands, brain and CNS, scrotum, and leukemia suggest etiologic similarities and possible treatment effects.

Entities:  

Mesh:

Year:  2005        PMID: 15880372     DOI: 10.1002/ijc.21064

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  43 in total

Review 1.  Why radioiodine remnant ablation is right for most patients with differentiated thyroid carcinoma.

Authors:  Frederik A Verburg; Markus Dietlein; Michael Lassmann; Markus Luster; Christoph Reiners
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03       Impact factor: 9.236

2.  (131)I treatment for thyroid cancer and the risk of developing salivary and lacrimal gland dysfunction and a second primary malignancy: a nationwide population-based cohort study.

Authors:  Kuan-Yin Ko; Chia-Hung Kao; Cheng-Li Lin; Wen-Sheng Huang; Ruoh-Fang Yen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-04-22       Impact factor: 9.236

Review 3.  The treatment of differentiated thyroid cancer in children: emphasis on surgical approach and radioactive iodine therapy.

Authors:  Scott A Rivkees; Ernest L Mazzaferri; Frederik A Verburg; Christoph Reiners; Markus Luster; Christopher K Breuer; Catherine A Dinauer; Robert Udelsman
Journal:  Endocr Rev       Date:  2011-08-31       Impact factor: 19.871

4.  Clinical presentations of thyroid cancer patients with multiple primary cancers.

Authors:  J D Lin; K J Lin; T C Chao; C Hseuh; N M Tsang; B Y Huang
Journal:  J Endocrinol Invest       Date:  2011-05-24       Impact factor: 4.256

5.  Second primary malignancies in renal cortical neoplasms: an updated evaluation from a single institution.

Authors:  Katie S Murray; Emily C Zabor; Massimiliano Spaliviero; Paul Russo; Wassim M Bazzi; John E Musser; A Ari Hakimi; Melanie L Bernstein; Guido Dalbagni; Jonathan A Coleman; Helena Furberg
Journal:  World J Urol       Date:  2016-04-22       Impact factor: 4.226

Review 6.  The Breast-Thyroid Cancer Link: A Systematic Review and Meta-analysis.

Authors:  Sarah M Nielsen; Michael G White; Susan Hong; Briseis Aschebrook-Kilfoy; Edwin L Kaplan; Peter Angelos; Swati A Kulkarni; Olufunmilayo I Olopade; Raymon H Grogan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-02       Impact factor: 4.254

7.  Multiple metachronous malignancies, one patient with three primary malignancies.

Authors:  Sangeetha Jayaraman; Somesh Balakrishnan; Devaji Rao
Journal:  Indian J Surg       Date:  2011-04-27       Impact factor: 0.656

8.  Synchronous and antecedent nonthyroidal malignancies in patients with papillary thyroid carcinoma.

Authors:  Sara E Murray; David F Schneider; Philip S Bauer; Rebecca S Sippel; Herbert Chen
Journal:  J Am Coll Surg       Date:  2013-03-20       Impact factor: 6.113

9.  Clinical significance of observation without repeated radioiodine therapy in differentiated thyroid carcinoma patients with positive surveillance whole-body scans and negative thyroglobulin.

Authors:  Dong-Jun Lim; Joo Hyun O; Min-Hee Kim; Ji-Hyun Kim; Hyuk-Sang Kwon; Sung-Hoon Kim; Moo-Il Kang; Bong-Yun Cha; Kwang-Woo Lee; Ho-Young Son
Journal:  Korean J Intern Med       Date:  2010-11-27       Impact factor: 2.884

10.  Discovery and identification of potential biomarkers of papillary thyroid carcinoma.

Authors:  Yuxia Fan; Linan Shi; Qiuliang Liu; Rui Dong; Qian Zhang; Shaobo Yang; Yingzhong Fan; Heying Yang; Peng Wu; Jiekai Yu; Shu Zheng; Fuquan Yang; Jiaxiang Wang
Journal:  Mol Cancer       Date:  2009-09-28       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.